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ABSTRACT 
Shijia Hu: Unraveling the Transcriptome of Odontogenic Tumors 
 (Under the direction of J. Timothy Wright) 
 
Odontogenic tumors, represent 31% of the oral tumors in children, are phenotypically 
diverse neoplasms of tissues that are responsible for tooth formation. Ameloblastoma and 
keratocystic odontogenic tumor, both believed to be derived from the odontogenic epithelium, 
constitute more than 50% of odontogenic tumors. Although both are usually slow-growing, 
they are locally invasive and have a recurrence rate as high as 50-80%. The lack of established 
adjunctive therapy means that surgical removal of the tumor with extensive margins to ensure 
complete excision remains the primary treatment of choice, resulting in significant morbidity.  
Tremendous advances are being made in the understanding of molecular mechanisms 
and pathways involved in tumorigenesis, improving diagnostic and therapeutic approaches. 
Most research on odontogenic tumors focused on candidate-genes with only a handful of 
studies employing whole genome and transcriptome approaches. Another limitation is the 
question of what normal tissue is most biologically-relevant for gene expression comparison 
with odontogenic tumors. Obtaining and characterizing the gene expression profile of 
odontogenic epithelium at different stages of differentiation will provide a biologically-relevant 
reference for comparison.  
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This study aims to bridge the current gap of knowledge in odontogenic tumor biology by 
characterizing the transcriptome of ameloblastoma and KCOT which up till this point has not 
been fully explored.  
The results showed that ameloblastoma separated into 2 distinct molecular clusters that 
were associated with 2 types of odontogenic tissue. Importantly, we found that 9/10 of the 
samples in the pre-secretory cluster were of the follicular type while 6/7 of the samples in the 
odontoblast cluster were of the plexiform type. Analysis of differential gene expression 
revealed alteration of common pathways in both clusters including cell cycle regulation, 
inflammatory and MAPkinase. Similarly, 2 distinct molecular subtypes of KCOT were found with 
several canonical inflammatory pathways activated in both subtypes of KCOT. Of note, the AKT 
pathway was activated in one subtype while MAPkinase pathway was activated in the other.  
Our results are suggestive of underlying molecular heterogeneity of odontogenic tumors 
which could indicate different receptiveness to treatment protocols. These findings have 
implications in the tailored use of chemotherapeutic agents or other treatment modalities. 
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CHAPTER 1: INTRODUCTION 
Odontogenic Tumors in Perspective 
Although odontogenic tumors are rare when compared to other head and neck tumors, 
they represent 31% of the oral tumors in children (Adebayo et al. 2002) and often are clinically 
challenging to manage. They represent a phenotypically diverse group of tumors that have 
shown differing prevalence among different populations, suggesting different genetic and/or 
environmental etiological factors. The 2 most prevalent odontogenic tumors are the 
ameloblastoma (Avelar et al. 2011) and keratocystic odontogenic tumor (KCOT) (Servato et al. 
2012). Both are believed to be derived from the odontogenic epithelium. Together, they 
constitute more than 50% of all odontogenic tumors (Buchner et al. 2006). 
Ameloblastoma is a slow-growing, locally invasive, benign epithelial odontogenic 
neoplasm. It is thought to arise from remnants of odontogenic epithelium of the tooth-forming 
enamel organ, also known as the cell rests of the dental lamina (Sehdev et al. 1974). This tumor 
exhibits epithelial cells resembling pre-ameloblasts on a basement membrane in loosely 
arranged cells resembling stellate reticulum while the stroma consists of loose connective 
tissue. Although rare, ameloblastoma has been known to show malignant potential (Bedi et al. 
2012) and occasionally metastasize (Luo et al. 2012). Currently, the WHO divides 
ameloblastoma into 4 subtypes namely, 1) solid, 2) peripheral, 3) desmoplastic, and 4) 
unicystic. Histopathologically, the solid and peripheral ameloblastoma subtype can be further 
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divided into a follicular and plexiform type while the much rarer unicystic ameloblastoma can 
be divided into the intraluminal and luminal types (Barnes L 2005). Current treatment 
modalities range from conservative enucleation and curettage for the unicystic subtype to 
radical maxillectomy for follicular subtypes (Singh et al. 2014). A striking feature of 
ameloblastoma is its penchant for recurrence with high recurrence rates (50-80%) being 
observed in cases of conservative treatment (Mendenhall et al. 2007). For this reason, and 
despite recent advances in imaging-assisted surgical margin localization, post-operative 
histological confirmation is still required. Meanwhile, intra-operative histological margin 
confirmation is challenging due to the calcified nature of the tumor and surrounding healthy 
tissue. This forces surgeons to either act conservatively risking the need for a second surgery, or 
act aggressively thus increasing morbidity (De Silva et al. 2012) and the need for extensive 
reconstructive surgery. This can be exceptionally devastating for young children due to their 
continued growth and development. Moreover, histological diagnosis can take up to 4 weeks 
and in cases of inadequate margins, patients will have to undergo further radiotherapy 
increasing the morbidity associated with radiation to the head and neck region. Recently, a case 
report of a recalcitrant stage 4 ameloblastoma carrying a BRAF V600E mutation was 
successfully treated with a combination of BRAF/MEK inhibitors (Kaye et al. 2015) raising the 
possibility of the increased use of chemotherapeutics in the treatment of ameloblastoma. 
In 2005, the World Health Organization reclassified the KCOT from a cyst to a tumor to 
better reflect its neoplastic nature (Barnes L 2005). KCOT is a benign but locally aggressive 
developmental cystic neoplasm historically thought to arise from the odontogenic epithelium 
and frequently is associated with the follicle of unerupted teeth (Partridge and Towers 1987). 
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Histological features includes a thin fibrous wall of connective tissue surrounding an epithelial 
layer of columnar, pallisading, hyperchromatic basal cells with a cystic lumen filled with keratin 
(Grasmuck and Nelson 2010). As with the ameloblastoma, it can in rare cases undergo 
malignant transformation (Tan et al. 2013). A high recurrence rate of up to 30% has been found 
following conservative treatment such as enucleation and curettage, creating a dilemma in 
determining the optimal extent of surgical resection to balance the risk of recurrence with the 
morbidity associated with extensive reconstruction. Although conservative treatment involving 
enucleation with application of Carnoy’s solution has recently been shown to be effective in 
reducing recurrence (Guler et al. 2012), larger lesions require more aggressive treatment. Of 
note, mutations in PTCH1, a tumor suppressor gene, causes the autosomal disorder Nevoid 
basal cell carcinoma syndrome (NBCCS) characterized by multiple basal cell carcinomas, KCOT 
and bifid ribs (Lam et al. 2013). These cases have higher recurrence rates when compared to 
isolated unifocal cases not associated with NBCCS (Johnson et al. 2012).  
Tumorigenesis: What is currently known about Ameloblastoma and KCOT 
Despite tremendous interest in these tumors, most published scholarship on this topic 
consists of case reports with a scant handful of genetic and molecular studies. Furthermore, in 
the majority of these studies, a bias selection of specific candidate genes or proteins were 
evaluated with little attention to genome-wide methods such as microarrays to describe the 
transcriptome of the tumors.  
Of the few molecular studies of ameloblastoma, differential expression of K-ras and 
Mitogen-activated protein kinase (MAPK) pathway were identified in 22 ameloblastomas with 1 
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tumor showing a K-ras mutation (Kumamoto et al. 2004b). The follow up study showed altered 
expression of activated members of the MAPK pathway in ameloblastomas suggesting an 
involvement in oncogenesis and tumor cell differentiation (Kumamoto and Ooya 2007). 
Recently, involvement of the MAPK pathway in ameloblastoma tumorigenesis was further 
explored. Specifically, a V600E mutation in BRAF was described by 3 different groups (Brown et 
al. 2014; Kurppa et al. 2014; Sweeney et al. 2014) with Kruppa and colleagues finding BRAF 
mutations in 63% of ameloblastomas. Additionally, transgenic mouse models carrying the v-Ha-
ras oncogene also have been found to develop ameloblastoma-like tumors spontaneously 
which is rare in the wild type variant (Dodds et al. 2003). Interestingly, activation of the nuclear 
mTOR pathway has been found to increase the recurrence of ameloblastomas by a factor of 6.4 
fold (Li et al. 2012). 
Molecular studies of KCOT have linked PTCH1 mutations to the aggressiveness and 
recurrence of KCOT with PTCH1 mutation associated with a higher recurrence rate; however, 
patients carrying PTCH1 mutation also have nevoid basal cell carcinoma syndrome (Kadlub et al. 
2013) while mutation of PTCH1 were found only infrequently (30%) in non-syndromic patients 
(Pan et al. 2009). Conversely, a recent study employing more sensitive techniques suggests that 
the proportion of sporadic KCOT with PTCH1 mutations could be greater than originally 
believed with up to 80% of the cases affected (Qu et al. 2015). To date, the entire PTCH1 
pathway has yet to be studied in the context of KCOT and other molecules in the pathway could 
be involved in isolated cases. The Sonic Hedgehog–Patched–Gli Pathway is a highly conserved 
and essential developmental pathway, with mutations being implicated in a number of birth 
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defects. If the pathway is aberrantly activated during adult life, it causes uncontrolled cell 
proliferation that manifests as cancer (Villavicencio et al. 2000). 
Interestingly, there are a number of genes and pathways that could be active and 
important in the tumorigenesis of both ameloblastoma and KCOT. The elevated expression of 
p53 and MDM2 has been implicated in the development of both ameloblastoma and KCOT 
(Kumamoto et al. 2004a; Sharifi-Sistani et al. 2011). Recently, there has been interest in the 
WNT pathway being involved in the pathogenesis of ameloblastoma and KCOT. The WNT 
pathways are essential for tooth development and altered expression of WNT associated genes 
had been found in ameloblastoma (Kibe et al. 2013) and KCOT (Hakim et al. 2011). Specifically, 
WNT5a was found to be highly expressed in a mouse tumor model (Sukarawan et al. 2010) 
leading to speculation that differential activation of these molecular pathways leads to 
tumorigenesis.  
Currently, there are 5 published microarray studies on human ameloblastoma and each 
relied upon different normal comparison tissues such as human gingiva (Carinci et al. 2003; 
Heikinheimo et al. 2015), human tooth buds (Heikinheimo et al. 2002), dentigerous cysts (Lim 
et al. 2006) and a universal human reference RNA (DeVilliers et al. 2011) to compare gene 
expression. This renders it impossible to compare the results across the different studies. The 2 
microarray studies on KCOTs used a 588 cancer-related human cDNA array against tooth buds 
(Heikinheimo et al. 2007) and a more extensive whole genome array against human gingival 
tissue (Heikinheimo et al. 2015). Although these studies provides valuable insight into the 
molecular basis of ameloblastoma and KCOT development, the lack of uniformity in choosing a 
reference tissue hampers the understanding of tumorigenesis of these odontogenic tumors. 
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This heterogeneity is a reflection of the lack of agreement on what constitutes the most 
biologically-relevant tissue for comparison. Given that odontogenic tumors are thought to be 
derived from the normal tissues involved in tooth formation, an appropriate comparison would 
be the normal odontogenic tissue transcriptome. 
The human dentome 
There is a need to address this lack of a normal tissue/cell‑of‑origin material for the 
examination of differential gene expression with the odontogenic tumors. The tissue of 
comparison will determine which genes and pathways are deemed different in the tumor. 
Using an inappropriate tissue for comparison can cloud the picture of pathways that are 
important to tumorigenesis. Ameloblastomas and KCOTs arise from the odontogenic 
epithelium. Obtaining the gene expression profile of odontogenic epithelium at different stages 
of development will help identify the tissue and developmental stage that most closely 
resembles the tumor tissue. This will aid in elucidating aberrant pathways present in 
odontogenic tumors compared with normal odontogenic tissue. 
Tooth formation or odontogenesis is strictly regulated at the molecular level and 
involves multiple complex processes including development of highly specialized cells that 
produce unique extracellular matrices and ultimately mineralized tissues. Human enamel and 
dentin formation involves cells derived from epithelial and mesenchymal tissues and in many 
ways is unlike any other hard tissue formation in the human body (Figure 1.1). 
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Figure 1.1: Development of ameloblast and odontoblast. Ameloblast is derived from 
ectodermal oral epithelium and undergo stages of differentiation (pre-secretory), secretory and 
maturation before undergoing apoptosis with the remaining cells contributing in the 
development of gingival attachment. Odontoblast is derived from the neural crest mesenchyme 
and remain functional throughout the tooth’s life. Both tissue exist in a pseudo-single layer 
while odontoblast is sandwiched by hard tissue (dentin) and a cell rich matrix (pulp). With 
permission from Dr. Tim Wright. 
 
The oral epithelium invaginates into the underlying mesenchymal tissue during the early 
stages of odontogenesis and gives rise to ameloblasts, the cells that form enamel. The 
ameloblasts undergo extensive histodifferentiation during their life cycle, going from cuboidal 
to columnar to squamous morphologies while creating and regulating a unique and changing 
microenvironment and extracellular matrix (Simmer et al. 2012). During the process of 
producing a unique extracellular matrix, the ameloblasts moves in a highly organized manner to 
produce enamel prisms that are oriented directionally into three dimensional species-specific 
patterns (Bartlett and Smith 2013). Once the full thickness of enamel has formed, the 
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ameloblasts alter their morphology again to facilitate maturation and further mineralization of 
the enamel. Upon completion of the enamel maturation process, the ameloblasts then become 
a protective covering until the tooth crown emerges into the oral cavity. At which point, most 
of the ameloblasts undergo apoptosis and cease to exist with the remaining cells contributing in 
the development of gingival attachment. Developing ameloblasts exist as a pseudo-single cell 
layer making it extremely challenging to the harvest and examine them. It is also known that 
some less differentiated cells of the dental lamina persists in the oral cavity (e.g. epithelial cell 
rests of Malassez) after odontogenesis and it is theorized that these cells undergo 
tumorigenesis and form odontogenic tumors (Juuri et al. 2013; Partridge and Towers 1987; 
Sehdev et al. 1974). 
In contrast, dentin-forming odontoblasts that are derived from the odontogenic 
mesenchyme continue to lay down matrix and remain functional throughout the tooth’s life 
(Couve et al. 2013). These cells are able to react to stimuli and lay down reparative or 
reactionary dentin when the tooth experiences environmental insults. During odontogenesis, 
ameloblasts from the dental epithelium are involved in molecular cross talk with the underlying 
mesenchymal cells which ultimately form odontoblasts (Jernvall and Thesleff 2000). Although 
odontoblasts persists throughout the life of the tooth, like ameloblasts, they present as a 
pseudo-single layer. In addition, the odontoblast cell layer is sandwiched between a highly 
mineralized layer (the dentin), and a cell rich layer (the pulp) making its study just as, if not 
more, difficult than ameloblast. 
Moreover, the acquisition of the transcriptome of odontogenic tissue (ameloblast and 
odontoblast), also known as the “dentome”, has potential impact in the study of other diseases 
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associated with ameloblast and odontoblast development and function such as tooth agenesis 
(Thesleff et al. 2001) and  amelogenesis imperfecta (Stephanopoulos et al. 2005). 
Investigative approaches 
Laser capture microdissection (LCM) is a technique that allows the isolation of specific 
cells from microscopic regions of tissue samples (Decarlo et al. 2011) (Figure 1.2). This 
technique can be applied to frozen sections (Hayashi et al. 2010) or archival tissues embedded 
in paraffin (Salmon et al. 2012). Because LCM does not change or damage the target cell 
morphology and chemical content, it has been coupled to high-density microarrays (Maxwell et 
al. 2013) to obtain expression profiles from specific cell populations. LCM has been shown to be 
able to isolate junctional epithelium of a thickness of 1-4 cells for gene expression studies, a 
level of precision not possible using traditional histological methods. This allows isolation and 
pooling of homogenous cell samples of the developing oral epithelium which is frequently only 
1 cell thick. The cystic nature of KCOTs and some subtypes of ameloblastomas also mean that 
the use of LCM will reduce the contamination of surrounding stroma tissue in the samples. 
Using this approach, we are able to obtain homogenous isolates of specific subpopulations of 
cells in complex samples (DeVilliers et al. 2011). The characterization of the odontogenic 
epithelium provides the opportunity to establish a consistent and reliable cell type for the 
comparison of differential gene expression between normal and tumor cells. 
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Figure 1.2: Micrograph of Laser microdissection. The arrow shows the cells of interest in all 
panels. Panel C shows the tissue left behind after LCM while panel D shows the capture of the 
target cells. With permission from Dr. Tim Wright. 
 
Whole genome microarray allows for entire transcriptome examination of target tissue 
samples providing a global picture of cellular activity. Traditionally, a 2-color microarray 
examines mRNA content between control and experimental tissue. Total RNA from the control 
sample is tagged with Cy3 while the experimental sample is tagged with Cy5. The labelled RNA 
is then hybridized to a chip containing oligonucleotide probes of interest and scanned for 
expression levels which is detected as differential luminescent color intensity depending on the 
level of expression present in the respective samples. When a standardized reference RNA is 
used between microarrays, it allows for the normalization across the microarray chips and 
experiments (Devonshire et al. 2010). Using this approach means that it will be possible to 
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compare data from future studies when the same commercially available standardized 
reference RNA is used for normalization. 
The development and refinement of molecular pathway analysis software aids in the 
analysis of gene expression data. Using this analytical approach allows us to build on existing 
knowledge from candidate gene studies, to examine upstream regulators and downstream 
effectors responses to gene expression changes of these genes of interest, as well as identify 
driver genes and derive a better understanding of the tumorigenesis of odontogenic tumors 
(Thomas and Bonchev 2010). Pathway analysis organizes genes into categories based on 
location, cellular components and reported molecular functions, facilitating assembly of nodes 
for the analysis of genetic networks and canonical pathways available in the database which 
will aid in our understanding of the pathogenesis of ameloblastoma and KCOT. Most diseases 
are complex and multi-factorial and result from the interaction of numerous genetic and 
environmental factors. The use of pathway analysis has advantages over the candidate gene 
approaches in this regard. The molecular approach using multi-omic techniques had helped 
unravel the molecular heterogeneity of breast cancer (Cancer Genome Atlas 2012) and 
understand the molecular pathogenesis of human hepatocellular carcinoma (Thorgeirsson and 
Grisham 2002). 
Future implications 
Characterization of the dentome will aid in the identification of genes and pathways not 
previously known to play a role in tooth formation. For example, the genes and pathways 
involved in cellular function such as ion and water regulation and cell movement, to name just a 
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couple, are likely controlling essential processes involved in normal odontogenesis and are 
worth closer examination. Unravelling the human dentome will advance our knowledge of 
tooth formation and the critical events that are regulated by gene expression and that control 
cell function and development of the tooth. This information can be used for establishing 
models for tooth development studies and ultimately pave the way for novel treatment for 
several tooth malformation disorders. For example, the use of a recombinant ectodsyplasin A in 
dogs can significantly reduce the burden of ectodermal dysplasia, a syndrome in human which 
includes multiple missing teeth (Casal et al. 2007). Establishing a good tooth development 
model can be used for developing similar novel therapeutics for the hundreds of hereditary 
defects affecting teeth.  
Comprehensive molecular portraits of many cancers utilizing whole transcriptome 
approaches (Cancer Genome Atlas 2012) have led to a better understanding of genomic 
aberrations and other events driving tumor biology. This knowledge is leading to the 
identification of therapeutically tractable pathways and more effective therapies. The current 
paucity of knowledge of tumorigenesis in odontogenic tumors means that treatment is still 
limited to surgical intervention and the need for extensive and devastating reconstructive 
surgery. Recently, chemotherapeutic agents have been used successfully in dogs for the 
treatment of ameloblastoma (Kelly et al. 2010). Of note, the SHH pathway inhibitor Vismodegib 
has been used as an adjunctive therapy in patients with NBCCS to reduce tumor size and reduce 
the margins needed for surgical resection (Booms et al. 2015). The use of chemotherapeutic 
agents to reduce tumor size can be very helpful in reducing recurrence and morbidity 
associated with extensive surgical margins.  
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Furthermore, we anticipate that the characterization of the transcriptome will elucidate 
molecular pathways and provide a rationale for the mutational analysis of genes strongly 
implicated in tumorigenesis. These findings can then be used to identify more specific 
molecular markers for tumor diagnosis and improve the identification of surgical margins using 
biological markers rather than traditional histopathology (Otero et al. 2013). As a corollary 
example, it was shown recently that the use of mass spectrometry to identify molecular 
markers in brain tumors correlated well with histological diagnosis, offering the potential for 
surgeons to maximize tumor resection while preserving function (Eberlin et al. 2013). A similar 
discovery of detectable molecular markers in odontogenic tumors could greatly enhance 
surgical margin determination and improve current treatment strategies. 
Conclusion 
In summary, this study aims to bridge the current gap of knowledge in odontogenic 
tumor biology by characterizing the transcriptome of ameloblastomas and KCOTs which up until 
now has not been fully explored. A comprehensive molecular profile can serve as a hypothesis-
generating resource for the advancement of precision medicine for the diagnosis and treatment 
of odontogenic tumors. In addition, the genes and pathways found to be associated with 
ameloblastoma and KCOT will provide a foundation for advancing our understanding of 
tumorigenesis, the development of new prognostic markers and ultimately novel treatment 
strategies. 
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Abstract 
 
The goal of the study was to characterize the transcriptome profiles of human 
ameloblasts and odontoblasts, evaluate molecular pathways and advance our knowledge of the 
human “dentome”. Laser capture microdissection was used to isolate odontoblasts and 
ameloblasts from human tooth buds (15-20week gestational age) from 4 fetuses. RNA was 
examined using Agilent 41k whole genome arrays at 2 different stages of enamel formation, 
presecretory and secretory. Probe detection was considered against the array negative control 
to control for background noise. Differential expression was examined using Significance 
Analysis of Microarrays (SAM) 4.0 between different cell types and developmental stages with a 
false discovery rate of 20%. Pathway analysis was conducted using Ingenuity Pathway Analysis 
software. We found that during primary tooth formation, odontoblasts expressed 14,802 
genes, presecretory ameloblasts 15,179 genes and secretory ameloblasts 14,526 genes. Genes 
known to be active during tooth development for each cell type (eg COL1A1, AMELX) were 
shown to be expressed by our approach. Exploring further into the list of differentially 
expressed genes between the motile odontoblasts and non-motile presecretory ameloblasts we 
found several genes of interest that could be involved in cell movement (FN1, LUM, ASTN1). 
Furthermore, our analysis indicated that the Phospholipase C and ERK5 pathways, that are 
important for cell movement, were activated in the motile odontoblasts. In addition our 
pathway analysis identified WNT3A and TGFB1 as important upstream contributors.  Recent 
studies implicate these genes in the development of Schimke immuno-osseous dysplasia. The 
utility of laser capture microdissection can be a valuable tool in the examination of specific 
tissues or cell populations present in human tooth buds. Advancing our knowledge of the 
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human dentome and related molecular pathways provides new insights into the complex 
mechanisms regulating odontogenesis and biomineralization. This knowledge could prove 
useful in future studies of odontogenic related pathologies.  
Introduction 
Tooth formation or odontogenesis is strictly regulated at the molecular level and 
involves multiple complex processes including development of highly specialized cells that 
produce unique extracellular matrices and ultimately mineralized tissues including the hardest 
tissue in the body, enamel (Thesleff et al. 2001). Ameloblasts, the cells that form enamel, 
undergo extensive histodifferentiation during their life cycle going from cuboidal to columnar to 
squamous morphologies while creating and regulating a unique and changing 
microenvironment and extracellular matrix (Deutsch et al. 1995; Simmer et al. 2012). During 
the process of producing a unique extracellular matrix, the ameloblasts move in a highly 
organized manner to produce enamel prisms that are directionally oriented into three 
dimensional patterns that are species specific (Bartlett and Smith 2013).  
Dentin forming odontoblasts, on the other hand, continue to lay down matrix and 
remain functional throughout the life of a tooth (Couve et al. 2013). These cells are able to 
react to stimuli and lay down reparative or reactionary dentin when the tooth experiences 
environmental insults. During odontogenesis, ameloblasts, derived from the dental epithelium, 
are involved in molecular cross talk with the underlying mesenchymal cells that ultimately form 
odontoblasts (Jernvall and Thesleff 2000). Many of the molecular mechanisms involved in tooth 
formation and the specific genes and interactions that control odontogenesis remain unknown. 
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The roles of specific genes and pathways involved in tooth development have been 
queried by numerous investigators using the murine model (D'Souza et al. 1999; Dassule and 
McMahon 1998; Jarvinen et al. 2006; Kim et al. 2012). Many human studies of odontogenesis 
have focused on single genes and pathways that are disease driven (Bergendal et al. 2011; Liu 
and Millar 2010; Rufini et al. 2011). The study of human odontogenesis is challenging due to the 
issue of obtaining samples at different developmental stages and the difficulty in isolating the 
different tissue components of the developing tooth bud. Most research has been based on the 
examination of entire tooth buds (Heikinheimo et al. 2002; Lin et al. 2007) which does not allow 
interrogation of the disparate tissues present in a developing tooth. 
Laser capture microdissection (Decarlo et al. 2011) allows the isolation of specific cells 
from microscopic regions of tissue samples (Chokechanachaisakul et al. 2012; Sun et al. 2012). 
Using this technique cells can be harvested from frozen sections or archival tissues embedded 
in paraffin (Hayashi et al. 2010; Salmon et al. 2012). As laser capture does not change or 
damage the target cell morphology and chemical content, it can be used for DNA, RNA or 
protein analyses. Recent development in microarray techniques and reduction in costs has led 
to novel approaches for the study of tissue and organ development (Heikinheimo et al. 2002; 
Tranasi et al. 2009). Microarray technology allows examination of the entire genome with very 
small samples thereby allowing targeted interrogation of gene expression. New bioinformatics 
approaches and the ability to examine entire pathways rather than individual genes is exciting 
as small changes in individual gene expression levels may be significant when examined in the 
context of overall pathway changes (Ganter et al. 2008).  
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The objective of this study was to characterize the gene expression profiles of human 
ameloblasts and odontoblasts and to further unravel the transcriptome of human teeth that we 
call the dentome. The investigation reveals many genes and molecular pathways not previously 
known to be involved in tooth formation that appear to be important. 
Materials and methods 
Tissue collection and preparation 
Written consent was obtained from mothers that were preparing for elective abortions 
in this IRB approved protocol through the University of North Carolina-Chapel Hill Office of 
Human Research Ethics. Four human fetuses were obtained at ages 15-20 weeks gestation, 
immediately placed on ice and the tooth buds dissected from the jaws, placed in RNAlater and 
refrigerated at 4C for 1-4 weeks to allow decalcification in Richard Allan Scientifics’ decalcifiying 
solution (ThermoScientific, Grand Island, NY, USA). The tissue was then frozen and stored at -
80oC. The tissue was sectioned at -35C at a thickness of 7 microns and lightly stained with 
haematoxylin and eosin to allow better visualization of the different cell types. Only anterior 
teeth from both the maxillary and mandibular jaws were used due to similar stage of dental 
development. 
Laser capture of specific tissue 
AutoPixTM automated LCM system from Arcturus (Arcturus Engineering, Santa Clara, CA, 
USA) was used to isolate the human odontoblasts and ameloblasts in different stages of enamel 
formation, using static image settings. Ameloblasts have different morphological features and 
organelle content during different stages of enamel formation. In this study ameloblasts were 
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assigned to specific developmental stages based on the presence or absence of visible enamel 
matrix at the light microscope level and cell morphology (e.g. presence of Tomes Process).  Cells 
isolated before enamel apposition were designated as being in the pre-secretory stage and if 
enamel extracellular matrix was visible the ameloblasts were classified as being in the secretory 
stage. Odontoblasts adjacent to the enamel epithelium secrete the predentin matrix and were 
harvested predominantly after some dentin matrix secretion.  This process allowed 
standardization of the cell’s developmental stage despite slight differences in an individual 
tooth bud’s stage of development. 
During the microdissection procedure, a CapSure (ThermoFisher, Grand Island, NY, USA) 
cap is positioned over the tissue section. At the end of the LCM procedure the transparent 
thermoplastic film that covers the cap was peeled off with the attached cells of interest and 
placed into RNA extraction buffer. Images were obtained of the tissue sections before and after 
LCM, including the captured regions.  
Total RNA was isolated from the microdissected cells with the PicoPure RNA Isolation kit 
(Arcturus Bioscience, Santa Clara, CA, USA). The quality and yield of total RNA were assessed on 
an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Samples from each cell 
type were then sent for analysis to determine the RNA Integrity Number (RIN). 
RNA Microarray 
Four samples each of odontoblasts, pre-secretory ameloblasts and secretory 
ameloblasts from 4 fetuses were obtained and RNA extracted.  The RNA from each CapSure cap 
was separately isolated and RNA from each individual tooth bud then pooled to obtain at least 
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200ng of RNA for each sample. This gave us a total of 4 different samples of each cell type for 
microarray analysis. Whole genome human oligonucleotide microarrays (41K Agilent) were 
used to examine gene expression of the different tissue. The arrays contain 44K 60-mer 
oligonucleotides representing over 41K human genes and transcripts.  
Two hundred nanograms of total RNA was converted into labeled cRNA with nucleotides 
coupled to fluorescent dye Cy3 using the Low RNA Input Linear Amplification Kit (Agilent 
Technologies, Palo Alto, CA) following the manufacturer’s protocol. The Human Universal 
Reference RNA from Stratagene (Santa Clara, CA, USA) was coupled with Cy5. 
Cy3-labeled cRNA (1.65 ng) from each sample was hybridized to Agilent whole genome 
array 41k formated chips. The hybridized array was then washed, scanned and data was 
extracted from the scanned image using Feature Extraction version 9.5 (Agilent Technologies, 
Palo Alto, CA). The microarray data is then submitted to the Gene Expression Omnibus (GEO) 
microarray database (accession number GSE63289). 
RTPCR 
RNA from a sample each of pre-secretory ameloblasts, secretory ameloblasts and 
odontoblasts were compared to the Human Universal Reference RNA from Stratagene by 
probing for high intensity, medium intensity and low intensity levels of expression based on the 
microarray data. The probes ACTIN, AMELX, COL6A3, FAM40B, HPRT1, IL11 were selected 
based on intensity levels obtained from the microarrays. RTPCR was performed using QIAGEN 
RT2 qPCR Primer Assays (Frederick ,MD, USA) in an Eppendorf Mastercycler gradient 
thermocycler. Experiments were repeated in triplicate. Intraclass correlation coefficient were 
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calculated between microarray log ratio and RTPCR expression ratio using SPSS 21 (IBM, 
Armonk, NY, USA). 
Data analysis 
Unbiased cluster analysis was carried out on the samples using Cluster 3.0 (open source) 
and the heat maps visualized using Java TreeView-1.1.6r2 (open source). 
For the expression data, each microarray was examined and the minimum intensity for 
expression was set at 95% confidence of the negative controls on that array. The lists were 
crossed referenced and only genes that were expressed in all 4 samples for each tissue type 
was determined to be expressed. Differential expression was examined using Significance 
analysis of microarrays (SAM) 4.0 between the different stages of ameloblasts and different 
tissues. The false discovery rates of the SAM analyses were set at 20%. 
Ingenuity pathway analysis was used to examine the pathways of the differential 
expression between the samples specifically focusing on the upstream analysis.     
Results 
We performed laser capture microdissection and microarray of 3 different cell types 
from tooth buds removed from 4 individual fetuses.  Cells from each fetus were analyzed 
separately. According to the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, 
USA), the microdissection yielded an estimated 10-15 ng total RNA per sample with a 260/280 
ratio between 2.12 and 2.14. The samples had an average RIN number of 5.4 ± 0.74 SD. 
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Genes expressed during tooth formation 
Laser capture microdissection allowed us to obtain small discrete areas of cells at 
relatively specific developmental stages from human tooth bud tissues (Figure 2.1).  Using the 
negative control spots to eliminate background at 95% confidence level, we found that during 
tooth formation odontoblasts expressed 14,802 genes, pre-secretory ameloblast expresses 
15,179 genes and secretory ameloblast expresses 14,526 genes.   
Differential gene expression in enamel and dentin formation 
To validate the overall gene expression levels observed in the microarrays we 
performed RTPCR on selected genes in the samples and compared them with the standard 
reference RNA used in the microarray. The RTPCR analysis showed a intraclass correlation 
coefficient of 0.838 (p<0.05) for single measures, suggesting good correlation for genes (ACTIN, 
AMELX, COL6A3, FAM40B, HPRT1, IL11) that had high, moderate and low levels of expression 
on the microarray (Figure 2.2).  
Using SAM analysis, we looked at differential gene expression between the different 
tissues at a false discovery rate of 20%. From the SAM plots (Figure 2.3) and unbiased cluster 
analysis (Figure 2.4), we observed that the greatest gene expression difference was between 
odontoblasts and pre-secretory ameloblasts.  
Odontoblasts had 131 genes expressed at significantly higher levels and 15 genes at 
lower levels compared with pre-secretory ameloblasts. In addition, 4 genes (ENAM, ASTN1, 
AMELX, SEZ6L) were expressed at lower levels in odontoblasts compared with secretory 
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ameloblasts; 4 genes (DMP1, AMBN, COPZ2, B3GALTL) were expressed at lower levels in pre-
secretory compared with secretory ameloblasts.  
 
Figure 2.1: The micrographs show the laser capture of a – odontoblasts, b - pre-secretory 
ameloblasts and c – secretory ameloblasts. The left panel shows pre-capture and area to be 
captured while the right panel shows post-capture and the removal of target cells. Scale bar: 50 
µm. 
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Figure 2.2: The graph shows comparison between the microarray Log ratio and RTPCR Log 
expression ratio. The microarray Log ratio is calculated using the ΔΔCt Method. Intraclass 
correlation coefficient analysis showed a significant correlation of 0.838 for single measure. 
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Figure 2.3: SAM plots: a – odontoblasts vs pre-secretory ameloblasts, b – odontoblast vs 
secretory ameloblasts, c – pre-secretory vs secretory ameloblasts. The red portion shows genes 
that are expressed at a higher level while the green portion shows genes that are expressed at a 
lower level with a FDR of 20%. 
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Figure 2.4: Heat map from cluster analysis. The map shows clustering of genes associated with 
collagen and extra cellular matrix formation. 
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Pathways important to enamel and dentin formation 
The Ingenuity Pathway Analysis program uses an extensive database of canonical 
pathways to analyze the differentially expressed genes, the pathways they are involved in and 
examine the activated and/or inhibited pathways. Pathway analysis shows that the 2 networks 
with the greatest difference between odontoblasts and pre-secretory ameloblasts are mainly 
collagen and NF-κB driven.  There were minimal differences for odontoblasts compared to 
secretory ameloblasts and pre-secretory compared to secretory ameloblasts.  
Some of the canonical pathways that are different between odontoblasts and pre-
secretory ameloblasts include - Intrinsic Prothrombin Activation Pathway, Hepatic Fibrosis / 
Hepatic Stellate Cell Activation, Atherosclerosis Signaling, Phospholipase C signaling, ERK5 
signaling and Sphingosine-1-phosphate signaling. (Table 2.1)   
Upstream Analysis 
An upstream analysis examines current levels of gene expression detected by the 
microarray analysis and predicts which upstream regulators were most likely to be involved. 
Our analysis indicated that numerous upstream regulators were predicted to be different 
between odontoblasts and pre-secretory ameloblasts. Of note we found that WNT3A, TGFB1, 
IGF2BP1, SHH, GLI1 and FGF2 were predicted to be significantly more active in odontoblast 
while Alpha catenin (Figure 2.5) was inhibited in odontoblasts when compared with pre-
secretory ameloblasts.   
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Figure 2.5: Upstream analysis: a – molecule network map for WNT3A, b – molecule network 
map for TGFB1, c – molecule network map for IGF2BP1, d – molecule network map for Alpha 
catenin. The predicted molecule is in the center with linkage to downstream targets based on 
differential expression from SAM analysis. The figure is generated through the use of QIAGEN’s 
Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). 
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Discussion 
Examination of murine tooth development using many different approaches suggested 
that more than 300 genes are involved in the tooth formation (Nieminen et al. 1998). More 
recently, the use of microarrays showed that 4362 genes are differentially expressed (Landin et 
al. 2012), suggesting that in fact large numbers of genes are involved. We showed that a much 
larger portion of the human genome is involved in the development of the human tooth. Many 
of the 14,802 genes and 15,179 genes expressed by odontoblasts and ameloblasts respectively 
are involved in basic cellular functions rather than tooth development specific functions. Other 
investigators found that various types of tissue express between 10,000 to 14,000 genes with 
an upper limit of 17,000 genes (Jongeneel et al. 2003). The present study clearly shows that the 
molecular control of odontogenesis is extremely complex and involves many more genes and 
molecular pathways than previously known.  
Our observation that secretory ameloblast expression profile was more similar to 
odontoblast expression as compared with pre-secretory ameloblast was unexpected. This 
finding is likely due to secretory ameloblasts and odontoblasts sharing many similar 
characteristics as both are differentiated cells, are secreting an extracellular matrix, are 
controlling the microenvironment of that matrix, and are motile and moving away from the 
secreted matrix. This is in contrast to the pre-secretory ameloblasts that are in the process of 
differentiation, are not motile, and not secreting an extracellular matrix. As ameloblasts 
differentiate and mature, their expression profile becomes more similar to that of odontoblasts 
with both cells functioning to produce a mineralized extracellular matrix that involves similar 
yet distinct processes (Figures 2.3 and 2.4). 
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As expected, the SAM analysis showed significantly higher expression of known dentin 
products such as collagen type 1, collagen type 3 in odontoblasts when compared to pre-
secretory ameloblasts. Our findings showed that the ENAM and AMELX genes which code for 
the enamel specific extracellular matrix proteins enamelin and amelogenin respectively were 
expressed at higher levels in enamel forming secretory ameloblasts. These differences in gene 
expression are reflective of the unique extracellular matrices produced by these different cell 
types and ultimately the compositionally and structurally different mineralized tissue they 
create.   
Interestingly, fibronectin (FN1) and lumican (LUM), showed greater levels of expression 
in odontoblasts compared with pre-secretory ameloblasts. The proteins derived from these 
genes are thought to be involved in the organization of extracellular matrix (Kadler et al. 2008; 
Matheson et al. 2005) that is secreted by the odontoblasts during dentinogenesis. In addition, 
lumican is also shown to affect actin organization in the cell cytoskeleton (Radwanska et al. 
2008) which has implications in the control of cell movement and shape. It is noteworthy that 
once the pre-secretory ameloblasts (non-motile cells) differentiate further to secretory 
ameloblasts (motile cells) FN1 and LUM are not differently expressed compared with the 
odontoblasts (motile cells). Furthermore, ASTN1, which codes for the neuronal protein 
astrotactin, is expressed at a higher level in secretory ameloblasts compared to odontoblasts. 
Astrotactin is a major player in the migration and movement of neurons (Wilson et al. 2010) 
and could be an important component in the control of ameloblast movement, potentially 
reflecting the ectodermal origin of ameloblasts and conservation of this protein function during 
enamel formation.  There is virtually nothing known about the complex regulation of motility in 
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these different odontogenic cell types but it is known that motility is critical in the normal 
formation and structure of the mineralized dentin and enamel. The other differentially 
expressed genes have been implicated in various other pathologies such as Peters' plus 
syndrome with cleft lip/palate (B3GALTL) (Schoner et al. 2013), tumor formation (COPZ2) 
(Shtutman et al. 2011) and lung cancer development (SEZ6L) (Gorlov et al. 2007) but have not 
yet been associated with tooth development. 
Not surprisingly, the top canonical pathways are driven by clusters of collagen genes 
(Intrinsic Prothrombin Activation Pathway, Hepatic Fibrosis / Hepatic Stellate Cell Activation, 
Atherosclerosis Signaling). Of note, the Phospholipase C signaling pathway is an important 
signal transduction pathway that is implicated in cancer development (Bunney and Katan 2010) 
and regulates chemotaxis through the modulation of Phosphoinositide 3-kinase activity to 
provide a direction-sensing machinery (Kolsch et al. 2008). In addition, the activation of ERK5 
signaling pathway is associated with disruption to cell actin cytoskeleton. This change in cell 
actin dynamics can lead to increased cell motility and decreased cell adhesion (Barros and 
Marshall 2005). Furthermore, Sphingosine-1-phosphate is thought to be a more potent 
chemoattractant of dental pulp stem cells than transforming growth factor β1 (TGF-β1), 
fibroblast growth factors (FGFs), and epidermal growth factors (EGFs) (Howard et al. 2010). 
Dental pulp stem cells are postulated to form reparative dentin in the event of tooth injury by 
migrating and differentiating into odontoblasts (Qvist 1975). The signaling pathways identified 
in this study could be contributing to the motility of odontoblasts compared to non-motile pre-
secretory ameloblasts. 
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Examination of upstream regulators showed that SHH, GLI1, FGF2 and TGFB1 are likely 
involved in dentinogenesis. This finding was expected as these genes have been well 
characterized to be involved in tooth formation and the disturbances of these genes are known 
to lead to tooth malformation and agenesis (Cobourne et al. 2001; Lee et al. 2011; Pispa et al. 
1999). Upstream analysis also indicated that both WNT3A and TGFB1 are activated in 
odontoblasts (Figure 2.5a-b). Recent investigation of Schimke immuno-osseous dysplasia, a 
syndrome associated with mutations of the SMARCAL1 gene shows there are cellular 
disturbance in the expression of WNT3A and TGFB1 as a result of abnormal SMARCAL1. Patients 
with this rare condition exhibit microdontia, hypodontia and severe molar root hypoplasia 
(Morimoto et al. 2012). These findings suggest that these pathways could be important in root 
formation and tooth morphogenesis. 
The present study also found that IGF2BP1 was identified as an active upstream 
regulator in odontoblasts (Figure 2.5c) and a human GWAS showed that it is one of the loci 
associated with tooth agenesis (Pillas et al. 2010). IGF2BP1 has also been implicated in the 
upregulation of betaTrCP1 leading to the activation of beta-catenin/Tcf signaling (Noubissi et al. 
2006) that is important in beta-actin mRNA translation and cell migration. This pathway 
provides a possible mechanism for the movement of odontoblasts as it deposits newly formed 
dentin. 
Conversely, Alpha catenin, that was predicted to be expressed at a lower level in 
odontoblasts when compared to pre-secretory ameloblasts (Figure 2.5d), is known to be 
important in ameloblast development (Sorkin et al. 2000). The cadherin–catenin complex, with 
Wnt/beta-catenin signaling, also has critical roles in regulating cell motility/adhesion (Van den 
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Bossche et al. 2012). The nature and complexity of movement has been shown to be quite 
different between odontoblasts and ameloblasts. A recent paper described the importance of 
MMP20 and the cadherin complexes during ameloblast maturation to allow movement of the 
epithelial cells by the switching of cadherin types (Guan and Bartlett 2013). 
One of the shortcomings of this study is that we were only able to obtain primary tooth 
buds for examination. It is likely that there are differences between the dentome of primary 
and permanent teeth; however, permanent tooth buds were not available in our study sample. 
Future studies of permanent tooth buds using similar protocols will shed light on the 
differences between the dentome of primary and permanent teeth. Later stages of tooth 
formation were not evaluated as the later stages of tooth formation (e.g. maturation) were not 
available. In addition, although the use of the LCM aids in providing a relatively discrete sample, 
there is still a possibility of contamination from adjacent cell layers such as the stratum 
intermedium collected with the ameloblasts. Furthermore, we did not analyze cementum or 
root forming cells, leaving the dentome incomplete at the moment.     
In summary, our results support the utility of laser capture microdissection as a valuable 
tool that allows interrogation of different tissues and cell types present in human teeth during 
different stages of development. The use of laser capture and RNA microarrays shows that the 
early developing human tooth transcriptome involves more genes than anticipated and diverse 
molecular pathways that are differentially activated in the tooth forming cells. We identified 
genes and pathways not previously known to play a role in tooth formation. For example, the 
genes and pathways involved in cell movement may be essential processes in normal 
odontogenesis that are worth closer examination. Unravelling the human dentome will advance 
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our knowledge of tooth formation and the critical events that are regulated by gene expression 
and that control cell function and development of the tooth. 
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Abstract 
Ameloblastoma is a slow growing, locally invasive benign epithelial odontogenic 
neoplasm derived from odontogenic epithelium. Although relatively rare, it makes up 40-50% 
of odontogenic tumors. A high recurrence rate of 50-80% with conservative treatment in some 
sub-types warrants radical surgical resections resulting in high morbidity. Ameloblastoma 
presents with diverse phenotypes which have yet to be characterized at the molecular level. 
The objective of the study was to characterize the transcriptome of ameloblastoma and identify 
relevant genes and molecular pathways using normal odontogenic tissue for comparison. 
Seventeen patients with ameloblastoma formed the study sample. Laser capture 
microdissection was used to obtain discrete samples of neoplastic epithelial tissue from excised 
tumors which were examined using the Agilent 44k whole genome microarray and the 
NanoString nCounter system. Odontogenic tissue transcriptome (human “dentome”) was used 
as reference for cluster, fold change, pathway and gene set enrichment analyses. The 
ameloblastomas separated into 2 distinct molecular clusters that were associated with 2 types 
of odontogenic tissue, namely pre-secretory ameloblast and odontoblast. Within the pre-
secretory cluster, 9/10 of ameloblastoma samples were of the follicular type while 6/7 of the 
samples in the odontoblast cluster were of the plexiform type (p<0.05). Analysis of differential 
gene expression revealed alteration of common pathways in both clusters including cell cycle 
regulation, inflammatory and MAP kinase. The pre-secretory ameloblast cluster exhibited 
higher activation of inflammatory pathways while the odontoblast cluster showed greater 
disturbances in transcription regulators. Known cancer-driving genes such as TP53 and 
members of the MAP kinase pathways were predicted to be altered in upstream analyses. Our 
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results are suggestive of underlying inter-tumor molecular heterogeneity of ameloblastoma, 
where different clinical phenotypes show different molecular signatures and involve different 
pathways. These findings highlight the molecular heterogeneity of ameloblastoma sub-types 
and may have implications in the tailored use of other treatment modalities. 
Introduction 
Ameloblastoma is a slow-growing, locally invasive, benign epithelial odontogenic 
neoplasm. It is thought to be arise from SOX2-expressing dental lamina epithelium (Juuri et al. 
2013), remnants of the tooth-forming enamel organ (Sehdev et al. 1974). The tumor exhibits 
epithelial cells resembling pre-ameloblasts on a basement membrane in loosely arranged cells 
resembling stellate reticulum while the stroma consists of loose connective tissue. Although 
odontogenic tumors are relatively rare, they constitute 3.8% of head and neck pathology, of 
which 40-50% are ameloblastoma (Avelar et al. 2011; Siriwardena et al. 2012). Occasionally, 
ameloblastomas show malignant features or transform into malignancy (Uzawa et al. 2015) and 
in rare cases metastasize (Luo et al. 2012). Current treatment modalities range from 
conservative enucleation to radical excision and vary according to tumor subtypes and location 
(Reichart et al. 1995; Singh et al. 2014). High recurrence rates (50-80%) have been observed in 
cases of conservative treatment (Mendenhall et al. 2007). Consequently, and despite recent 
advances in imaging-assisted surgical margin localization, post-operative histological 
confirmation is still required. This forces surgeons to either act conservatively, risking the need 
for a second surgery, or act aggressively thus increasing morbidity (De Silva et al. 2012) and the 
need for extensive reconstructive surgery.  
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There are few genomics and transcriptomics studies of ameloblastoma, with most 
investigations focusing on candidate-genes. Moreover, different comparison tissues were used 
in the handful of microarray studies; including gingival tissue (Carinci et al. 2003; Heikinheimo 
et al. 2015b), whole tooth buds (Heikinheimo et al. 2002), dentigerous cysts (Lim et al. 2006) 
and a universal human reference RNA (DeVilliers et al. 2011). Furthermore, whole tumor 
samples were used in these studies which includes large portions of stromal tissue. In spite of 
the heterogeneity in comparison tissue, there have been advances in understanding 
tumorigenesis of ameloblastoma.  
A recent study examining the whole transcriptome of ameloblastoma suggested the 
existence of distinct molecular subtypes (Heikinheimo et al. 2015b). It is envisaged that better 
understanding of the molecular basis of ameloblastoma can aid the identification of diagnostic 
and prognostic markers and may lead to the development of novel, personalized treatment 
protocols (Gomes et al. 2014). To address this knowledge gap, we embarked on this study 
aiming to characterize the transcriptome of neoplastic ameloblastoma tissue and identify 
relevant molecular pathways and genes, using a whole genome microarray.  
Materials and methods 
Tumor collection and preparation 
Written informed consent was obtained from 17 subjects diagnosed with 
ameloblastoma and slated to undergo surgical treatment at the University of North Carolina 
(UNC) Department of Oral and Maxillofacial Surgery in this IRB-approved study. Between 2005 
and 2008, 2 fresh frozen samples were obtained during surgical resection and 15 formalin-fixed 
 42 
 
paraffin-embedded (FFPE) samples were retrieved from the archives of the Department of Oral 
and Maxillofacial Pathology Laboratory, UNC School of Dentistry. All samples were evaluated by 
a board-certified oral and maxillofacial pathologist and at least one other author and diagnoses 
were classified based on the 2005 WHO Histologic Classification of Odontogenic Tumors. 
Additional demographic data including gender, age, race, and tumor recurrence were recorded 
and examined for potential associations. 
Dissected tumors were placed in RNAlater and Richard Allan Scientifics’ decalcifying 
solution (water, hydrochloric acid, EDTA, tetrasodium tartrate and potassium tartrate) at 4oC 
for 1-4 weeks before 7µm sections were obtained under RNAse-free conditions (DeVilliers et al. 
2011). The sections were then used for laser capture microdissection (LCM). 
Laser capture microdissection  
The ability of LCM to isolate one cell-thick discrete tissue populations (Hayashi et al. 
2010) facilitates the targeting and pooling of neoplastic epithelial portions of ameloblastoma. 
The AutoPixTM automated LCM system (Arcturus Engineering, Santa Clara, CA, USA) was used to 
isolate tumor cells (basal epithelial cells adjacent to the basement membrane). Images of the 
tissue sections including the captured regions were obtained before and after LCM.  
RNA extraction and microarray 
Laser-captured cells from each tumor were pooled and total RNA was isolated with the 
PicoPure RNA Isolation kit (Arcturus Bioscience, Santa Clara, CA, USA). The Agilent Bioanalyzer 
2100 (Agilent Technologies, Palo Alto, CA, USA) was used to assess the yield and quality of total 
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RNA. Amplification was completed on all samples using TargetAmpTM 2-Round Aminoallyl-aRNA 
Amplification Kit (Epicentre Biotechnologies, Madison, WI, USA). RIN values ranged from 2.3 to 
4.9 with a mean of 3.0 ± 0.85. 
RNA was then analyzed using whole genome human oligonucleotide microarrays (41K 
Agilent) containing 44 thousand 60-mer oligonucleotides representing over 41 thousand human 
genes and transcripts. For this step, 200ng of RNA was converted into labeled cRNA with 
nucleotides coupled to fluorescent dye Cy3 using the Low RNA Input Linear Amplification Kit 
(Agilent Technologies, Palo Alto, CA) according to the manufacturer’s protocol. The Human 
Universal Reference RNA from Stratagene (Santa Clara, CA, USA) was coupled with Cy5. Cy3-
labeled cRNA (1.65 ng) from each sample and the Cy5-labeled universal reference was 
hybridized to the Agilent whole genome array 41k formatted chips. Data were extracted using 
Feature Extraction version 9.5 (Agilent Technologies, Palo Alto, CA). Background subtraction 
and Loess normalization were performed using default setting of the Agilent extractor. The use 
of the universal RNA facilitated the use of the dentome as a comparison. It acts as a technical 
intra/inter normalizing control, decreasing variability by measuring signal output ratio of 
experimental to reference RNA rather than relying on absolute signal intensity two-color 
hybridization experiments (Novoradovskaya et al. 2004). The dentome consists of odontogenic 
tissue (microdissected samples of human odontoblasts, pre-secretory ameloblasts and 
secretory ameloblasts) expression data from previous work that employed the universal 
reference as a normalizing control (Hu et al. 2015). The data set included 4 samples of each 
type of odontogenic tissue. It was collected from 12 anterior tooth buds (incisor and canine) 
from 4 different fetuses with each fetus contributing 3 tooth buds. Each type of odontogenic 
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tissue was collected from a single tooth bud with each of the 3 buds providing a single type of 
odontogenic tissue or developmental stage. (Gene Expression Omnibus microarray database 
accession number GSE63289) 
The ameloblastoma expression data were submitted to the Gene Expression Omnibus 
microarray database (accession number GSE68531). 
Microarray data analysis 
A multiclass analysis was conducted between the 3 types of odontogenic tissue and the 
60 genes differentially expressed at a false discovery rate (FDR) < 20% were designated as the 
odontogenic tissue-defining genes. The most appropriate comparison tissue was decided to be 
the normal tissue with the most similar profile to ameloblastoma, such that identified 
differences would be tumor specific. Cluster analysis was conducted using Cluster 3.0 between 
the 3 normal and tumor samples and visualized using Java TreeView-1.1.6r2.  
Differential gene expression between tumors and comparison tissue were examined 
using Significance analysis of microarrays (SAM) 4.0. Ingenuity pathway analysis was used to 
identify differentially expressed pathways. In addition, upstream analysis from the ingenuity 
pathway analysis software was conducted. Gene set enrichment analysis (GSEA) (Subramanian 
et al. 2005) was conducted using GSEA v2.1.0 from the Broad institute (Cambridge, MA, USA) 
and the “all curated gene sets v4.0” available via the Molecular Signatures Database (MSigDB) 
(Liberzon et al. 2011). Additionally, the ameloblastoma transcriptome was compared with the 
13 cancer molecular subtypes from The Cancer Genome Atlas (TCGA) project (Hoadley et al. 
2014) to investigate possible correlation with other known cancer types. 
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Microarray gene expression validation using NanoString  
A variety of approaches have been used to validate microarray data in the literature and 
NanoString was selected for the study. A random subset of 3 ameloblastoma and 2 control 
odontogenic tissue samples was used to validate the microarray gene expression data. 
NanoString nCounter (Seattle, WA, USA) high throughput gene expression analysis (Geiss et al. 
2008) was performed using the Human Cancer Reference codeset 
(http://www.nanostring.com/products/gene_expression_panels). Each reaction contained 50 
ng of total sample RNA plus reporter and capture probes. Digital counts were extracted, 
normalized and analyzed using nSolver v2.5 software. Differential expression between 
ameloblastoma and pre-secretory ameloblast from nanoString was compared with that 
obtained from the microarray. 
Results 
LCM facilitated the isolation of basal epithelial (neoplastic) cells from the tumor samples 
(Figure 3.1) without contamination from surrounding stroma cells. RNA was extracted from the 
LCM samples, with the 260/280 ratio for the 17 samples between 1.7-2.1 and a yield of 
between 88ng to 928ng. Quality control analysis conducted on the microarray chips indicated 
expected values for positive and negative controls, as well as uniformly high detected genes in 
both the red and green channels.  Overall, no outliers were detected in either the normal tissue 
or tumor arrays indicating consistency in hybridization between samples. 
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NanoString validation  
Fold changes obtained with the nCounter system were correlated with those obtained 
from the microarray for the same samples (Table 3.1). The 2 sets of expression data showed a 
good Pearson correlation (r = 0.61) in the scatter-plot (Figure 3.2).  
Determination of comparison tissue 
Unsupervised hierarchical cluster analysis was conducted for the tumor and normal 
tissue samples which showed the presence of 2 distinct clusters of ameloblastoma and a 
separate cluster of normal odontogenic tissue (Figure 3.3). Supervised cluster analysis using the 
60 odontogenic tissue defining genes showed that the 2 clusters of ameloblastoma associated 
most closely with pre-secretory ameloblast (PA) and odontoblast (OB) (Figure 3.4A, 4B). As 
such, these 2 clusters were designated as the pre-secretory ameloblast-like ameloblastoma 
(pAM) and odontoblast-like ameloblastoma (oAM), respectively. Out of 10 samples in the pAM 
cluster, 9 were of the follicular type while 6/7 of the samples in the oAM cluster were of the 
plexiform type. (Figure 3.4C). A Chi-square analysis showed that the molecular clusters were 
significantly associated with a histological subtype (p<0.05). A single comparison tissue could 
not be designated as the 2 clusters associated most closely with different odontogenic tissue; 
instead, a multiclass approach was employed. 
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Figure 3.1: The micrographs show the laser capture of the epithelial portion of an 
ameloblastoma sample. A – light micrograph of follicular ameloblastoma at 4X showing tumor 
epithelial follicles that are single-cell thick with surrounding stroma, B – laser capture outline of 
epithelial cells, C – remnants of the stroma tissue after LCM  and D – captured cells on capsure 
cap. Scale bar: 100 µm. 
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Figure 3.2: Scatterplot of Microarray (x-axis) differential expression versus NanoString (y-axis) 
differential expression. There is Pearson’s correlation of 0.61 between the 2 platforms.  
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Figure 3.3: Unsupervised hierarchical cluster analysis of reference tissue with tumor samples. 
3126 genes with the greatest standard deviation between the samples were used for the 
cluster analysis. 
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Figure 3.4: Cluster analysis used to determine reference tissue. A – Heat map of the 3 different 
odontogenic tissue (OB – Odontoblast, PA – Pre-secretory ameloblast, SA – Secretory 
ameloblast) and the 2 distinct clusters of Ameloblastoma (AM) clustered using the 60 
odontogenic epithelium-defining genes. B – Array tree showing grouping of the 2 clusters with 
odontoblast and pre-secretory ameloblast. C – Demographics and tumor phenotype.   
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Multiclass analysis 
Multiclass analysis was conducted between the 2 tumor clusters and 2 associated 
normal tissue (pAM, oAM, PA, OB) and differentially expressed genes were carried forward in a 
cluster analysis (Figure 3.5A). To characterize the transcriptome of ameloblastoma and the 2 
molecular sub-clusters, the gene expression data were analyzed in 3 groups. The common 
tumor cluster describes differential gene expression common in both tumor clusters compared 
to normal tissue and comprises 2592 genes that were expressed at a higher and lower level in 
the 2 tumor clusters (pAM, oAM) compared to the 2 normal tissue clusters (OB, PA). The pAM 
cluster describes differential gene expression unique to that cluster and consists of 1287 genes 
expressed at higher and lower levels compared to the other 3 groups. The oAM cluster 
describes differential gene expression unique to oAM tumors and consists of 1516 genes 
expressed at a higher and lower levels compared to the other 3 groups. The genes with fold 
changes at FDR < 1% were used for pathway analysis (Data uploaded at 
http://genomewide.net/public/transcriptome/ameloblastoma/Supplemental_Table_2.xlsx ).  
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Figure 3.5: Multiclass and pathway analysis of the different tumor clusters. A – Heat map of 
the genes with a FDR < 1% that are differentially expressed in the 4 clusters (OB – odontoblast, 
PA – pre-Secretory Ameloblast, oAM – odontoblast-like ameloblastoma, pAM – pre-secretory 
Ameloblast-like ameloblastoma) from a SAM multiclass analysis. The cluster tree on the right 
showed the 2 distinct clusters of ameloblastoma. Groups of genes with similar expression 
(identified by colored bars at the bottom of the heat map) were used for pathway analysis for 
the different clusters of ameloblastoma which were shown in B-D. B – Canonical pathways that 
are differentially expressed for the Common tumor cluster in IPA. C – Canonical pathways that 
are differentially expressed for the Pre-secretory ameloblast cluster in IPA. D – Canonical 
pathways that are differentially expressed for the odontoblast cluster in IPA. The figures (B-D) 
are generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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Pathway and gene set enrichment analysis  
Ingenuity pathway analysis was used to examine the activated and inhibited canonical 
pathways for each tumor cluster (Table 3.2).  
The common tumor cluster had 21 activated (z-score>1) and 5 inhibited (z-score <-1) 
pathways (Figure 3.5B) at p-value<0.05. Genes associated with notable biological processes that 
were differentially expressed in all the ameloblastoma tumors included prevention of damage 
to cell cycle regulation, cancer pathways, inflammatory pathways and Map kinase related 
pathways. In addition, GSEA conducted between the common tumor cluster and normal tissues 
showed that 1860 out of the 2381 genes sets in the “all curated gene sets v4.0” were up-
regulated in the common tumor cluster. Nineteen upregulated gene sets were significantly 
enriched at the nominal p-value<0.05. (Table 3.3).  
The pre-secretory ameloblast tumor cluster had 22 activated and 1 inhibited pathway 
below the critical p-value threshold (Figure 3.5C). Pathway analysis showed activation in the 
known cancer pathways, several inflammatory pathways and EGFR pathways. 
The odontoblast tumor cluster had 1 activated and 8 inhibited pathways (Figure 3.5D). 
Several inflammatory pathways were found to be inhibited in this cluster. 
Upstream analysis  
Upstream regulators that were predicted to be activated or inhibited are listed in Table 
3.4. Most of the predicted upstream regulators in the common tumor cluster were transcription 
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regulators, kinases and cytokines. Specifically, several Map kinase members and inflammatory 
cytokines were predicted to be activated.  
Correlation with The Cancer Genome Atlas 
The 2 molecular subtypes of ameloblastoma were compared with the transcriptome of 
the cancer subtypes in TCGA (Figure 3.6). The analysis did not show any significant correlation 
of ameloblastoma with any of the 13 subtypes of cancers that are well studied and has 
established treatment protocols. As ameloblastoma does not seem to correlate molecularly 
with the cancer subtypes, more investigation into ameloblastoma tumorigenesis is needed for 
the development of effective treatment. 
 
 59 
 
 
 60 
 
 
 61 
 
 
 62 
 
 
Figure 3.6: Correlation analysis with The Cancer Genome Atlas subtypes. This suggests no 
significant correlation between ameloblastoma and the 13 cancer subtypes. 
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Discussion 
The major finding of this study was the molecular heterogeneity of ameloblastoma that 
was strongly associated with its histological subtypes. Gene expression profiles of follicular and 
plexiform subtypes were more closely related to gene expression profiles of different normal 
odontogenic tissues and the follicular subtype showed activation of different molecular 
pathways compared with the plexiform subtype. This new knowledge can serve as a rich 
hypothesis-generating resource for the study of molecular and phenotypic characteristics of 
ameloblastoma.  
Similar to the present study, Heikinheimo and colleagues found that ameloblastoma 
gene expression is heterogeneous, and identified 2 distinct tumor clusters with gene expression 
profile that were most similar to gene expression in the cap/bell stage of tooth development 
(Heikinheimo et al. 2015b). Using supervised cluster analysis we found that more than half of 
ameloblastoma samples were most similar in gene expression to pre-secretory ameloblast, 
similar to those observed in the early cap/bell stage as described by Heikinheimo. It was 
surprising that using the supervised cluster analysis the remaining ameloblastoma samples 
associated with mesenchymal derived odontoblasts rather than with the epithelial derived 
ameloblasts. This finding appears to be driven by differences in inflammatory pathways and 
was associated with a different histological appearance.  
The examination of pathways common to both tumors show that inflammation appears 
to play an important role in ameloblastoma tumorigenesis and proliferation. Canonical pathway 
analysis showed that several immune/inflammatory pathways are activated in addition to 
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several predicted activated upstream cytokines. The association between dysregulated 
inflammation and cancer progression has been studied extensively (Coussens and Werb 2002). 
The greater number of pathways activated in the pre-secretory cluster suggests that this 
process may be more important in the follicular subtype. 
Additionally, both tumor clusters revealed that damage to cell cycle regulation pathways 
play important roles. A key regulator in the cell cycle damage prevention pathways is TP53 
which is also predicted to be inhibited in our upstream analysis. TP53 is a major tumor 
suppression gene (Rivlin et al. 2011) and the loss of a tumor suppressor gene activity in 
ameloblastoma may be important in the tumorigenesis process.  
Several canonical pathways involving the MAPK pathways and upstream members were 
found to be activated in the common tumor cluster. The MAPK pathways have long been 
considered tumor driver pathways in the pathogenesis of various cancers and also is thought to 
be important in ameloblastoma tumorigenesis (Brown et al. 2014; Sweeney et al. 2014). 
Recently, Kurppa and colleagues found BRAF gene mutations, specifically V600E mutation, in 
63% of ameloblastomas (Kurppa et al. 2014). BRAF is in the RAS pathway and MAPK cascade. 
The V600E mutation in BRAF is a promising oncogene target for the anti-neoplastic drug 
dabrafenib; which was used in conjunction with a MEK inhibitor in a patient with stage 4 
ameloblastoma with good results (Kaye et al. 2015). The use of chemotherapeutic agents to 
reduce tumor size can be very helpful in cases of ameloblastoma requiring extensive surgical 
margins and major post-surgical reconstruction (Heikinheimo et al. 2015a).  
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In GSEA, the gene sets with the highest activation scores, were cancer related including 
“SMID_BREAST_CANCER_LUMINAL_A_DN”. Cancer related pathways were also found to be 
differentially expressed in our pathway analysis. Moreover, breast cancer specific “Role of 
BRCA1 in DNA Damage Response” pathway was found to be differentially expressed, with the 2 
different analyses highlighting similar molecular pathways.   
One of the short-comings of this study is that most of the samples were FFPE. Formalin 
fixing can cause the degradation of RNA (Ravo et al. 2008) and affect the accuracy of 
microarrays. However, recent studies supported the use of such samples for gene expression 
analysis (Abdueva et al. 2010) and NanoString has been shown to produce consistent results 
independent of the sample type (fresh frozen versus FFPE) (Malkov et al. 2009). Genes in our 
microarray data that had the greatest fold changes showed good correlation with the 
nanoString expression. In addition, there were no outliers in the cluster analysis among the 
ameloblastoma cluster analysis indicating consistent results between fresh frozen and FFPE 
samples.  
Strengths of the study included the use of LCM and universal RNA as a means of 
normalizing between arrays. Ameloblastoma presents with neoplastic epithelial tissue 
surrounded by stromal tissue making isolation very difficult. As a result, most investigations of 
ameloblastoma used samples that contain diverse cell populations such as the surrounding 
stroma which can obscure driver pathways from the actual neoplastic epithelial cells. The use of 
the universal RNA facilitated the use of the dentome as a comparison and also allows the use of 
the microarray data by other investigators using universal RNA for normalization.   
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In conclusion, our study isolated ameloblastoma epithelial and normal odontogenic cells 
using LCM to identify gene expression profiles and molecular pathways that are potentially 
important in the tumorigenesis of ameloblastoma. Ameloblastoma showed 2 distinct molecular 
profiles that were associated with different histological subtypes suggesting they could be 
receptive to different chemotherapeutic protocols. These results provide a wealth of 
information that can be used in future experimental and mechanistic studies, involving animal 
models and new pharmacogenomic approaches. 
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Abstract 
Keratocystic Odontogenic Tumor (KCOT) is a locally aggressive developmental cystic 
neoplasm thought to arise from the odontogenic epithelium. A high recurrence rate of up to 
30% has been found following conservative treatment. Aggressive tumor resection can lead to 
the need for extensive reconstructive surgery, resulting in significant morbidity and impacting 
quality of life. Most research has focused on candidate-genes with a handful of studies 
employing whole transcriptome approaches. There is also the question of which reference 
tissue is most biologically-relevant. This study characterizes the transcriptome of KCOT using 
whole genome microarray and compare it with gene expression of different odontogenic 
tissues (“dentome”). Laser capture microdissection was used to isolate the neoplastic epithelial 
tissue in 20 cases. KCOT gene expression was compared with the “dentome” and relevant 
pathways were examined. Cluster analysis revealed 2 distinct molecular subtypes of KCOT. 
Several inflammatory pathways were activated in both subtypes. The AKT pathway was 
activated in one subtype while MAP kinase pathway was activated in the other. Additionally, 
PTCH1 expression was downregulated in both clusters suggesting involvement in KCOT 
tumorigenesis. In conclusion, this study provides new insights into the transcriptome of KCOT 
and highlights pathways that could be of diagnostic and prognostic value. 
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Introduction 
In 2005, the World Health Organization reclassified the Keratocystic Odontogenic Tumor 
(KCOT) from a cyst to a tumor to better reflect its neoplastic nature (Barnes L 2005). KCOT is a 
benign but locally aggressive developmental cystic neoplasm historically thought to arise from 
the odontogenic epithelium (Partridge and Towers 1987) and frequently is associated with the 
follicle of unerupted teeth. During the last decade there has been a resurgence of interest in 
and efforts to understand tumorigenesis of KCOTs with the ultimate goal of developing better 
diagnostic and treatment approaches. 
Despite advancements in antineoplastic therapies, surgical intervention remains the 
treatment of choice for KCOTs. A high recurrence rate of up to 30% has been found following 
conservative treatment such as enucleation and curettage, creating a challenge in determining 
the optimal extent of surgical resection. Nevoid basal cell carcinoma syndrome (NBCCS) is a 
disorder that presents with multifocal KCOT; these cases have even higher recurrence rates 
when compared to isolated unifocal cases not associated with NBCCS (Johnson et al. 2013). 
Aggressive tumor resection can lead to the need for extensive reconstructive surgery and 
rehabilitation for patients with KCOTs, causing significant morbidity and negatively impact their 
quality of life.     
Little is known about the molecular profile of KCOTs; however, recent reports have shed 
some light on molecular pathways driving the tumorigenesis of KCOT. For example, the PTCH1 
pathway has been the primary focus of candidate-gene studies due to its association with the 
NBCCS (Guo et al. 2013; Kadlub et al. 2013; Qu et al. 2015). Other potential aberrant pathways 
 70 
 
including SHH (Ren et al. 2012), WNT signaling (Hakim et al. 2011), p53 (Alur et al. 2014) and 
matrix metalloproteinases (Amm et al. 2014) are of interest. These candidate-gene studies aid 
in the advancement of precision medicine (Collins and Varmus 2015) for improved diagnostics 
for predicting prognosis and managing KCOT. However, only 2 published studies to date have 
used next-generation approaches including genomics and transcriptomics methods to 
characterize the tumorigenesis of KCOT. In a 2007 report, Heikinheimo et al used a 588 cancer-
related human cDNA array (Heikinheimo et al. 2007) for the study of KCOT and more recently 
they employed a more extensive whole genome array (Heikinheimo et al. 2015). These studies 
provided valuable initial insights into the molecular basis of KCOT development. 
Unraveling the molecular basis of KCOT can help identify altered pathways involved in 
its tumorigenesis, as well as discover potentially informative cell markers for its diagnosis and 
treatment. Thus, the objective of this study was to characterize the transcriptome of KCOTs 
using a whole genome microarray and compare it with the expression profile of a biologically-
relevant odontogenic tissue (referred to as “dentome”) (Hu et al. 2015).  
Materials and methods 
Patient recruitment and sample collection 
The study was conducted in accordance with approved human subject research 
guidelines and was approved by the local institutional review board and the ethics committee 
of the University of North Carolina-Chapel Hill. Patients diagnosed with isolated KCOT and 
scheduled for tumor removal at the Department of Oral and Maxillofacial Surgery at the 
University of North Carolina-Chapel Hill between 2005 and 2008 formed the study sample. All 
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participants (N=20) provided written informed consent. Diagnosis of KCOT was confirmed by a 
board-certified oral pathologist and another investigator using the 2005 WHO Histologic 
Classification of Odontogenic Tumors. Patients presenting with NBCCS were excluded from this 
study. Six fresh frozen samples were obtained during the surgical procedures and 14 formalin-
fixed paraffin-embedded (FFPE) samples were obtained from the Department of Oral and 
Maxillofacial Pathology at UNC-Chapel Hill after their histological diagnosis was confirmed. 
Potential associations of gene expression with participants’ demographic characteristics 
including gender, age, race, and tumor recurrence were examined using bivariate methods 
(Fisher’s exact test) and a conventional p<0.05 statistical significance criterion. 
Sample preparation  
All 20 samples were decalcified for 1-4 weeks using a solution containing water, 
hydrochloric acid, EDTA, tetrasodium tartrate and potassium sodium tartrate from Richard 
Allan Scientifics (ThermoScientific, Grand Island, NY, USA). The samples were then sectioned at 
-35oC at a thickness of 7 microns and lightly stained with hematoxylin and eosin. These slides 
were then used for the microdissection of target tumor epithelial cells. 
Laser capture microdissection (LCM) (Sun et al. 2012) is a technique that allows the 
isolation of tissue that is 1 cell thick. KCOT is a cystic tumor containing loose surrounding 
stroma and a keratotic layer that arises from a neoplastic basal layer with numerous satellite 
cysts (Figure 4.1A and 4.1B). LCM allowed isolation of discrete areas of the basal neoplastic 
layer (Fig. 4.1C and 4.1D) for the examination of a purer cell population. The technique has 
been successfully used in microarray studies for both fresh (Hayashi et al. 2010) and formalin 
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fixed samples (Salmon et al. 2012). The AutoPixTM automated system (Arcturus Engineering, 
Santa Clara, CA, USA) was used for LCM. The captured cells were pooled for each sample and 
placed in RNA extraction buffer. RNA was isolated from the tumor cells using the PicoPure RNA 
Isolation kit (Arcturus Bioscience, Santa Clara, CA, USA). The quality and yield of total RNA were 
assessed using the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). 
Microarray analysis 
Agilent whole genome human oligonucleotide microarrays which contain 44 thousand 
60-mer oligonucleotides representing over 41 thousand probes and transcripts was used for 
whole transcriptome analysis. The Human Universal Reference RNA from Stratagene (Santa 
Clara, CA, USA) served as a control to standardize hybridization levels between microarrays and 
was coupled to Cy5. Two hundred nanograms of total RNA from the KCOT samples were 
converted into labeled cRNA with nucleotides coupled to fluorescent dye Cy3 using the Low 
RNA Input Linear Amplification Kit (Agilent Technologies, Palo Alto, CA). The Cy3-labeled cRNA 
(1.65 ng) from each sample and Cy5 coupled universal reference RNA was hybridized to whole 
genome array formatted chips. The hybridized array was washed, scanned and data extracted 
from the scanned image using Feature Extraction version 9.5 (Agilent Technologies, Palo Alto, 
CA). 
The microarray data were submitted to the Gene Expression Omnibus (GEO) microarray 
database (accession number GSE68532). 
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Figure 4.1: The micrographs show the laser capture of the epithelial portion of a KCOT 
sample. A – light micrograph of KCOT at 4X showing formation of satellite cysts, B – laser 
capture outline of epithelial cells showing target basal epithelial cells, C – remnants of the 
stroma tissue after LCM  and D – captured cells on Capsure cap. Scale bar: 100 µm. 
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Determination of reference tissue and bioinformatics analysis 
Human odontogenic tissue whole transcriptome data, also known as the “dentome” was 
used to help identify the most appropriate (based on being the most similar) odontogenic 
reference tissue to be used for comparison with the tumor samples. As part of earlier work 
conducted by our group, multiple embryonic teeth were used to obtain 4 samples each of 
human odontoblasts, pre-secretory ameloblasts and secretory ameloblasts using 
microdissection to isolate discrete samples of the different cell types and development stages 
from which gene expression data were obtained. (Gene Expression Omnibus microarray 
database accession number GSE63289) (Hu et al. 2015). Multiclass significance analysis of 
microarrays 4.0 (SAM) was conducted between the 3 types of normal odontogenic tissue and 
60 genes were found to be expressed differentially at a FDR of < 20%. A cluster analysis, using 
these 60 genes that differentiated the normal odontogenic tissue, was conducted using Cluster 
3.0 between the KCOT samples and the normal odontogenic tissues. Results of this analysis 
between normal odontogenic tissues and KCOT were then visualized using Java TreeView-
1.1.6r2 to establish the normal tissue with a gene expression profile most similar to KCOT. 
Gene set enrichment analysis (GSEA) (Subramanian et al. 2005) was conducted with 
GSEA v2.1.0 from the Broad institute (Cambridge, MA, USA) using the Molecular Signatures 
Database (MSigDB) curated gene set(Liberzon et al. 2011) “all curated gene sets v4.0” and 1000 
permutations. Differential expression between the tumor and comparison normal tissue was 
calculated with SAM. Genes of interest were carried forward and interrogated using the 
Ingenuity pathway analysis (IPA), including canonical pathway and upstream analyses. 
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Upstream analysis is a model that predicts activation or inhibition of upstream regulators based 
on the expression levels of downstream molecules. The model has the advantage of detecting 
genes with possible gain-of-function mutation that did not show an increase level of expression.  
Microarray data validation via NanoString analysis 
The NanoString nCounter system (Seattle, WA, USA) was used to validate the microarray 
gene expression data. The nCounter system is based on a direct multiplexed measurement of 
gene expression and offers high levels of precision and sensitivity (Malkov et al. 2009). The 
nCounter Human Cancer Reference codeset 
(http://www.nanostring.com/products/gene_expression_panels) which profiles 230 cancer-
related human genes and 6 internal reference genes was used. In this analysis, the microarray 
data of a subset of 3 KCOT and 2 normal secretory ameloblast samples were examined. 
Hybridization reactions were performed using 50 ng of total RNA with reporter and capture 
probes, in accordance to the manufacturer’s instructions. The NanoString nCounter digital 
count readings were extracted, normalized and analyzed using nSolver v2.5 to obtain fold-
change values between KCOT and normal tissue. These data were then compared to the 
corresponding KCOT and normal tissue microarray fold change values. A scatterplot was 
constructed using the 20 most upregulated and downregulated genes in the nanoString analysis 
between KCOT and secretory ameloblast with differential expression from the microarray data 
(Table 4.1). The 2 sets of data showed good correlation (r-0.65) between the microarray and 
nanoString data for genes showing the highest fold change differences (Figure 4.2). 
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Figure 4.2: Scatterplot of Microarray differential expression versus NanoString differential 
expression. Microarray fold change is on the x-axis while NanoString fold change is on the y-
axis. 
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Results 
RNA extracted from the LCM samples had a 260/280 ratio of between 2.17 and 2.20 and 
a yield of between 914ng to 1225ng per sample, demonstrating reasonable quality and yield.  
Reference tissue and multiclass analysis 
When cluster analysis was conducted with the 60 odontogenic tissue defining genes, the 
KCOT samples appeared to cluster into 2 distinct molecular subtypes (Figure 4.3A). One of the 
subtypes clustered with secretory ameloblast (SA) while the other clustered with odontoblast 
(OB), as such the clusters were designated as secretory ameloblast-like KCOT (sKC) and 
odontoblast-like KCOT (oKC) respectively. In order to confirm the finding of 2 distinct subtypes, 
an unsupervised cluster analysis of all the genes were performed with the 20 KCOT samples. 
The tumor samples separated into 2 distinct subtypes as shown in the cluster tree (Figure 4.3B). 
The Fisher exact test did not show significant association of the clusters (Figure 4.3C) with race, 
recurrence, gender, tumor type or age. 
The discovery of 2 distinct molecular clusters of KCOT did not allow the designation of a 
single normal odontogenic tissue for gene expression comparison, as such, a multiclass analysis 
approach was employed. SAM multiclass analysis of genes differentially expressed at a FDR < 
1% was conducted between the 2 KCOT clusters (sKC, oKC) and 2 associated normal tissues (SA, 
OB) (Figure 4.4A) (Data uploaded at 
http://genomewide.net/public/transcriptome/kcot/Supplemental_Table_2.xlsx). The gene 
expression data were analyzed in 3 clusters. The “common tumor cluster” consists of 3166 
genes which were differentially expressed in the 2 tumor clusters (sKC, oKC) compared to the 2  
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Figure 4.3: Cluster analysis to determine reference tissue. A – Heat map of the 3 different 
odontogenic tissues (OB – Odontoblast, PA – Pre-secretory ameloblast, SA – Secretory 
ameloblast) and KCOT (KC) clustered using the 60 odontogenic tissue defining genes. B – Array 
tree showing 2 clusters of the 2 KCOT molecular subtypes (odontoblast and secretory 
ameloblast clusters). C – Demographics and tumor recurrence  
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Figure 4.4: Multiclass analysis and pathway analysis of the different tumor clusters. A – Heat 
map of the genes with a FDR < 1% that are differentially expressed in the 4 clusters (OB – 
odontoblast, SA – Secretory Ameloblast, oKC – odontoblast-like KCOT, sKC – secretory 
ameloblast-like KCOT) from a SAM multiclass analysis. The color bars on the right of the heat 
map shows the groups of genes used to define each cluster’s differential gene expression. B – 
Canonical pathways that are differentially expressed for the common tumor cluster in IPA. C – 
Canonical pathways that are differentially expressed for the secretory ameloblast cluster in IPA. 
D – Canonical pathways that are differentially expressed for the odontoblast cluster in IPA. The 
figures (B-D) are generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, 
QIAGEN Redwood City, www.qiagen.com/ingenuity). 
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normal tissue clusters (OB, SA). The “secretory ameloblast cluster” consists of the 985 
differentially expressed genes in the sKC cluster compared to the other 3 groups. The 
“odontoblast cluster” consists of 902 differentially expressed genes in the oKC cluster 
compared to the other 3 groups. The fold changes were then used for pathway and GSEA 
analyses. 
Canonical pathways and gene set enrichment analysis  
Ingenuity pathway analysis was used to examine the activated and inhibited canonical 
pathways for each tumor cluster. Canonical pathways with an absolute z-score > 1 and p-value 
< 0.05 are presented in Table 4.2 showing the pathways exhibiting the greatest 
activation/inhibition that were significantly different.  
The common tumor cluster had 18 activated and 5 inhibited pathways (Figure 4.4B). 
There were 7 pathways involved in cell cycle regulation. Notably, 6 Inflammatory (Immune) 
response/cytokine signaling pathways were found to be differentially expressed in addition to 5 
Cellular growth, proliferation and apoptosis pathways and 3 Cancer pathways. GSEA conducted 
between the common tumor cluster and normal tissues showed that 14 gene sets were 
significantly enriched (nominal p-value < 0.05) and 1 gene set was inhibited (nominal p-value < 
0.05) (Table 4.3). Specifically, the Sonic hedgehog signaling (SHH/PTCH1) pathway was not 
found to be significantly differentially expressed between normal and tumor tissue. Closer 
examination of the SHH/PTCH1 pathway showed downregulation of PTCH1 and its downstream 
target GLI without changes to SHH (Figure 4.5). 
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Figure 4.5: Sonic hedgehog signaling pathway. The upregulated and downregulated molecules 
of the pathway is shown according to the legend. 
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The sKC cluster had 2 activated and 20 inhibited pathways (Figure 4.4C). All 
Inflammatory (Immune) response/cytokine signaling pathways and most of the Cellular growth, 
proliferation and apoptosis pathways were found to be inhibited except for the PI3K/AKT 
Signaling pathway. 
The oKC cluster had 38 activated and 2 inhibited pathways (Figure 4.4D). Most of these 
pathways involved Cellular growth, proliferation and apoptosis. Activation of MAP kinase-
related pathways were also noted. 
Upstream analysis 
Table 4.4 presents predicted differentially activated genes with p-values < 0.05 along 
with the corresponding z-scores. In the common tumor cluster, 21 molecules were predicted to 
be inhibited and 57 to be activated when compared to normal tissue. These upstream 
molecules were mainly transcription regulators (21 molecules), cytokines (10 molecules) and 
kinases (8 molecules). Two molecules were predicted to be activated in the secretory 
ameloblast tumor sKC cluster, namely the complex Cg and cytokine CSF2. In addition, 3 
transcription regulators and 2 kinases were predicted to have differential activity in the 
odontoblast cluster. 
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Discussion 
A major finding of this study was the discovery of 2 distinct clusters of KCOT that exhibit 
similar phenotype despite differences in molecular pathway activity. In addition, PTCH1 and GLI 
expression were found to be downregulated in both clusters suggesting involvement in the 
tumorigenesis of non-NBCCS associated KCOT. Moreover, the study provides a comprehensive 
characterization of KCOT transcriptome that can serve as a hypothesis-generating resource for 
the advancement of precision medicine for the diagnosis and treatment of KCOT. 
The finding of 2 distinct molecular clusters was in contrast to the findings of 
Heikinheimo et al. who described a more homogeneous profile of KCOT (Heikinheimo et al. 
2015). However, comparing the findings of the 2 studies is difficult due to the use of gingiva 
tissue as the comparison tissue in their study. In the present study we interrogated the human 
“Dentome” to determine what tissue was most similar in gene expression profile to KCOT. It 
remains unclear what would be the optimal comparative oral tissue to use to help delineate 
differential gene expression in KCOT or other odontogenic tumors. Our use of a universal RNA 
allows for the normalization between arrays within the study and also can be used across 
studies which employ the universal RNA as an internal standardization that allows better 
comparison from one array to another.  
The present study did find that most KCOT showed gene expression profiles that more 
closely resemble secretory ameloblast which is a differentiated cell type of the dental lamina 
from which KCOT is thought to arise. However, it is surprising that a smaller subset of tumors 
showed a gene expression profile more closely associated with odontoblast that is derived from 
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a mesenchymal cell lineage. Differences in the 2 molecular subtypes includes activation of 
PI3K/AKT Signaling in sKC and activation of the MAP kinase pathway in oKC. Earlier studies have 
found activation of the AKT pathway in KCOT (Chaisuparat et al. 2013) which have been 
extensively targeted in cancers for therapy (Hennessy et al. 2005) and may provide a novel 
treatment modality for this particular subtype of KCOT. Conversely, the oKC subtype had 
activation of 3 MAP kinase associated pathways. The MAP kinase pathway has been implicated 
in KCOT development (Gonzalez Moles et al. 2008). In addition, the oKC subtype showed 
activation of numerous Cellular growth, proliferation and apoptosis pathways that were not 
seen in the sKC subtype including the JAK/STAT pathway. Recently, a trial targeted this pathway 
in solid tumors with good results (Houghton et al. 2014) which could be explored as an 
adjunctive therapy before surgery to reduce the size of the tumors and thus extent of resection 
and reconstruction needed to reduce the high recurrence rate of KCOT.  
The canonical pathway that showed the biggest difference in the “common tumor 
cluster” was the activation of the Acute Phase Response Signaling pathway. Additionally, 5 
other inflammatory pathways were activated in the common tumor cluster compared to the 
normal tissue. Other investigators (Cottom et al. 2012; Kadlub et al. 2013) described the 
presence of inflammation around KCOT and a possible link between the presence of 
inflammation and the aggressiveness of the tumor. Furthermore, upstream analysis predicted 
the activation of several pro-inflammatory markers. GSEA also showed several inflammatory 
gene sets that were enriched in KCOT.  
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In addition, several cell cycle mechanism pathways and GSEA gene sets were found to 
be disturbed, corresponding to the uncontrolled proliferation found in the neoplasm. Upstream 
analysis also predicted inhibition of CDKN1A which has been implicated heavily in DNA damage 
response (Cazzalini et al. 2010) and control of cell cycles to prevent proliferation of neoplastic 
cells. Other notable upstream molecules predicted to be upregulated include members of the 
MAP kinase pathways such as JUN, MAP3K14, ERK and JNK, all of which have been heavily 
implicated with the development of cancers (Dhillon et al. 2007). 
The SHH/PTCH1 pathway which is known to cause NBCCS (OMIM # 10940), was 
specifically interrogated. Individuals with NBCCS have PTCH1 mutations and presents clinically 
with multiple and recurrent KCOT as well as other neoplasms (e.g. basal cell carcinoma). 
Historically, mutations in the PTCH1 gene were found in more than 85% of syndromic KCOT but 
less than 30% of sporadic cases. More recent studies suggest that the proportion of sporadic 
KCOT with PTCH1 mutations could be greater than originally believed with up to 80% of the 
cases affected (Qu et al. 2015). Although our study did not investigate the prevalence of PTCH1 
mutation, we found that the expression level of PTCH1 in KCOT was decreased. The PTCH1 gene 
functions as an important tumor suppressor (Kadlub et al. 2013; Pan et al. 2009) which when 
suppressed, can lead to development of tumors. More importantly, the SHH pathway inhibitor 
Vismodegib has been used as an adjunctive therapy in patients with NBCCS to reduce tumor 
size and reduce the margins needed for surgical resection (Booms et al. 2015). Currently, 
chemotherapeutic adjuncts are seldom used in sporadic cases; although they may be helpful in 
cases with decreased PTCH1 expression in limiting tumor size, surgical margins and recurrence. 
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Although a large portion of the KCOT samples were FFPE which can result in RNA 
degradation (Ravo et al. 2008) and affect the performance of microarray analyses, previous 
studies supported the use of such samples (Abdueva et al. 2010). Furthermore, NanoString 
analysis has been used for expression analysis in various sample types including fresh-frozen, 
FFPE and even whole cell lysates to produce excellent results (Malkov et al. 2009). Despite the 
issue of RNA degradation in FFPE samples, there was good correlation between the microarray 
and nanoString expression data for genes with the greatest fold changes. Another short-coming 
is the limited sample size of 20 tumors which is due to KCOT being a relatively rare tumor. 
However, it is comparable to other similar studies with sample sizes ranging from 10-12 
(Heikinheimo et al. 2007; Heikinheimo et al. 2015).  
In conclusion, this study provides new insights into the transcriptome of KCOT using a 
method that provided purer sample populations of neoplastic epithelial cells. By comparing the 
KCOT transcriptome to the available “dentome”, we found familiar pathways that have been 
implicated in the formation of KCOT and other cancers. This is in addition to novel pathways 
that may serve as markers for diagnosis and prognosis. Possible targets for novel therapy were 
also identified in this study and should be investigated further to development precision 
medicine for the treatment of KCOT. Future studies should take into account the 2 distinct 
molecular subtypes when developing specific treatment modalities in order to maximize 
effectiveness. 
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CHAPTER 5: FINAL THOUGHTS AND FUTURE DIRECTIONS 
The work presented in this dissertation contributes to our understanding of the 
molecular mechanisms involved in the tumorigenesis of odontogenic tumors and to advance 
the development of the field of precision medicine for the treatment of odontogenic tumors. In 
this dissertation, we presented the transcriptome of different odontogenic tissues at different 
stages of development (the dentome) and used this new information to compare gene 
expression profiles between normal and pathological odontogenic tissues. This represented a 
shift in the selection of normal comparison tissue for the examination of odontogenic tumor 
gene expression. By making this data freely available, we anticipate that future investigations of 
odontogenic tumors will adopt the concept of comparing tumor transcriptome to normal 
odontogenic tissue which will make the results more comparable between studies. 
In this study, we made several important discoveries about gene expression differences 
between different odontogenic tissues. In the dentome portion of this study, we found that the 
early developing human tooth transcriptome involved more genes than anticipated. In addition, 
many diverse molecular pathways, not previously thought to be involved in the tooth formation 
process, were differentially activated in the tooth-forming cells. One important example is that 
we found genes and pathways involved in cell movement that may be essential for processes in 
normal odontogenesis and are worth closer examination. For example, future molecular studies 
could examine the role of Astrotactin, a major player in the migration and movement of 
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neurons (Adams et al. 2002). We identified high levels of Astrotactin mRNA suggesting the 
protein may be involved in the motility of maturing ameloblast. Understanding these processes 
is important in the advancement of technologies related to tissue engineering in the production 
of laboratory-grown replacement teeth for patients suffering from conditions with multiple 
congenitally missing teeth such as ectodermal dysplasia. 
Also of note is the number of dentome defining genes that we found in our multiclass 
analysis between the odontogenic tissues. We found that there were only 60 differentially 
expressed genes out of upwards of 14,000 genes expressed by odontogenic tissue during 
normal development. Multiple differentially expressed genes in this group of 60 genes were 
identified that could be tissue defining genes. Investigators may be able to utilize this 
information for the development of viable odontogenic cell lines and models that are currently 
lacking. Development of ameloblast and odontoblast cell lines that replicate normal cell 
function would be of great importance to the field. The possible candidate genes include SOX5, 
which is highly expressed in odontoblasts but not ameloblasts, a transcriptional regulator 
involved in the regulation of embryonic development (Kawasaki et al. 2015) and may determine 
the differentiation of mesenchyme cells into odontoblasts. On the other hand, KRT19 was 
found to be highly expressed in ameloblasts at both stages of development but not 
odontoblasts. KRT19 has been implicated in the development of other tissue such as 
chondrocytes (Rodrigues-Pinto et al. 2016) but may prove to be an important marker in the 
development of odontogenic epithelium. 
In the second paper, we found and reported that ameloblastoma presented with 2 
distinct molecular profiles that were associated with 2 histological subtypes. Inter/intra tumor 
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heterogeneity has been described in many cancer types, including breast cancer, melanoma 
and prostate cancer with genomic instability, epigenetic changes and the tumor 
microenvironment implicated as factors causing gene expression heterogeneity (Burrell et al. 
2013). This introduces significant challenges in designing effective treatment strategies 
ultimately resulting in treatment resistance after initial tumor shrinkage. The follicular 
ameloblastoma subtype showed activation of different molecular pathways compared with the 
plexiform subtype, suggesting that they could be receptive to different chemotherapeutic 
protocols. Recent advancements in understanding the tumorigenesis of ameloblastoma have 
opened up the possibility of novel chemotherapeutic treatment for recalcitrant disease, such as 
the successful treatment of recurrent stage 4 ameloblastoma with BRAF and MEK inhibitors 
(Kaye et al. 2015).  
There are several promising targets for therapy from the canonical pathway and 
upstream analysis, including transcription factors TP53 and EZH2. The guardian gene TP53 is 
one of the most important genes in tumor development, acting as a powerful tumor 
suppressor. It is important in cell cycle regulation, initiating DNA repair during cell division and 
signaling the cell to undergo apoptosis when DNA damage cannot be corrected. Recently, there 
have been attempts to target TP53 in cancer treatment including gene therapy to reintroduce 
wild type TP53, targeting cells that have lost TP53 with an adenovirus to destroy them and the 
use of small molecules to upregulate the expression of TP53 (Wang and Sun 2010). In our study, 
the frequent inhibition of TP53 in ameloblastoma suggests that the patients would probably 
benefit from TP53 targeted treatment. In addition, we found that EZH2 was predicted to be 
activated in ameloblastomas. EZH2 is responsible for the methylation levels of histone3K27, an 
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epigenetic change that determines the expression levels of many genes. Overexpression of 
EZH2 can lead to suppression of important tumor suppressor genes and have been implicated 
in several human cancers (Yoo and Hennighausen 2012). Investigators have made rapid 
progress in the development of anti-EZH2 therapy with some showing great promise in the use 
of a protein inhibitor in the treatment of lymphoma (McCabe et al. 2012). Therefore, targeting 
EZH2 may be a viable therapy in the treatment of human ameloblastomas.  
Another promising target group of pathways is the Inflammatory/immune. The link 
between inflammation dysregulation and cancer is not a new one, with several anti-
inflammatory agents such as NSAIDS, COX-2 inhibitors and corticosteroids being studied as 
possible therapeutic agents (Rayburn et al. 2009). We found increased expression of 
inflammatory and immune gene products in laser captured neoplastic cells which suggests that 
these tumors produce inflammatory cytokines normally provided by immune cells. This 
implicates inflammatory pathways as viable targets in the development of adjunct therapies in 
the treatment of ameloblastomas. However, it is also important to note that the pre-secretory 
cluster (follicular ameloblastoma) showed much more activated inflammatory pathways 
compared to the odontoblast cluster (plexiform ameloblastoma). Future research should 
examine if the differences at the molecular level affects the response of the different subtypes 
of ameloblastoma to chemotherapeutic agents. This has the potential of improving treatment 
approaches to reduce morbidity and recurrence rates. 
In the third paper, we found activation of familiar pathways, such as PTCH1, that have 
been implicated in the formation of multifocal KCOT in NBCCS. However, our data suggest that 
disturbances to the SHH/PTCH1 pathway are also important in isolated cases too. This finding 
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affirms existing knowledge of the suspected molecular drivers in the tumorigenesis of KCOT and 
strengthens the case for employing currently available protocols targeting these pathways. 
Such as the use of Vismodegib, a SHH pathway inhibitor currently used in the treatment of 
NBCCS (Booms et al. 2015), in the treatment of isolated cases of KCOT. Alternatively, 
downstream targets of PTCH1 can be targeted as well. Other investigators targeted the 
smoothen gene in KCOT cell lines with cyclopamine that killed the tumor cells (Ren et al. 2012). 
We can hypothesize from our results, that the GLI genes downstream of PTCH1 and smoothen 
may be viable targets. As with ameloblastoma, inflammatory dysregulation appears to be an 
important component in the development of KCOT. Targeting the inflammatory pathways in 
KCOT could prove to be a viable chemotherapeutic adjunct in the treatment of KCOT.  
Several transcription regulators implicated in cancer development were also predicted 
to be disturbed in our study including the activation of EZH2, HIF1A and inhibition of TP53. The 
implications of EZH2 and TP53 disturbance were discussed earlier in the ameloblastoma 
section. Activation of HIF1A is found in numerous human cancers and promotes tumor growth 
via promotion of angiogenesis and regulation of cellular hypoxia (Talks et al. 2000). HIF1A is an 
important factor in solid tumor growth and has been targeted successfully in other human 
cancers. There are currently many approaches to inhibit HIF1A (Onnis et al. 2009) and should be 
examined for their effectiveness on KCOT.  
In addition, we discovered 2 distinct clusters of KCOT gene expression profiles that 
exhibit similar phenotypes despite differences in molecular pathway activity. We found that the 
AKT pathway is activated in the secretory ameloblast cluster while the MAPKinase pathways is 
activated in the odontoblast cluster. This could explain the variable expression found by earlier 
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studies when these pathways were examined in isolation. Activated AKT was found in only 40% 
(Chaisuparat et al. 2013) of KCOT in an immunohistological study with activated ERK, the 
effector of the MAPKinase pathway, found in 60% (Ribeiro et al. 2012) of KCOT in another 
study. These findings suggest that future treatment of KCOT should examine the possibility of 
the 2 distinct molecular subtypes responding differently to treatment protocols and the use of 
additional diagnostic tools to clinically identify the different clusters. Another treatment 
strategy is the use of combination therapy targeting multiple pathways to combat the issue of 
intra/inter tumor heterogeneity. AKT inhibitors (Alexander 2011) can be combined with 
inhibitors of the members of the MAPKinase cascade (Sebolt-Leopold 2000) RAF, MEK and ERK, 
as an adjunct for the treatment of KCOT to target the different clonal populations, maximizing 
effectiveness and reducing treatment resistance. 
In the near future, the rapidly advancing field of gene expression study will be able to 
employ techniques with higher resolution and be better able to amalgamate information from 
fields such as genomics and proteomics to form a clearer picture of the tumorigenesis of 
odontogenic tumors. Future studies will also benefit from high throughput methods such as 
deep sequencing that allow for the examination of alternatively spliced transcripts, post-
transcriptional modifications and gene mutations. In addition to mRNA, other important 
populations of RNA such as miRNA, tRNA, and rRNA which are intimately involved in the final 
expression of protein products are likely informative and should be examined. Using available 
bioinformatics tools, we can superimpose information from genomic and proteomic studies 
with gene expression to provide an atlas of odontogenic tumors akin to The Cancer Genome 
Atlas currently being complied for the major cancer types.  
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In this age of rapid information sharing, we can overcome another shortcoming of the 
work presented here, which is the small sample size of tumors. Odontogenic tumors are 
relatively rare. Therefore, providing a standardized method of gene expression study with a 
comparable internal control, such as a universal human RNA or using digital methods such as 
RNA-seq, will allow the pooling of more samples and rare subtypes and better examination of 
the involved molecular pathways.   
In conclusion, we provided a detailed characterization of ameloblastoma and KCOT 
transcriptome that can serve as a hypothesis-generating resource for the advancement of 
precision medicine for the diagnosis and treatment of these odontogenic tumors. 
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